• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

作者信息

Eyre Toby A, Fox Christopher P, Boden Ali, Bloor Adrian, Dungawalla Moez, Shankara Paneesha, Went Richard, Schuh Anna H

机构信息

Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.

Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

出版信息

Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22.

DOI:10.1111/bjh.15151
PMID:29468637
Abstract
摘要

相似文献

1
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.idelalisib联合利妥昔单抗可使TP53基因缺失的B-PLL获得持久缓解，但会导致显著毒性：英国范围内同情用药项目的更新结果
Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22.
2
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.idelalisib联合利妥昔单抗可诱导TP53基因功能缺失的B细胞原淋巴细胞白血病患者实现临床缓解。
Br J Haematol. 2017 May;177(3):486-491. doi: 10.1111/bjh.14066. Epub 2016 Apr 7.
3
Idelalisib-related pneumonitis.依地利斯布相关肺炎
Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25.
4
Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.低剂量伊布替尼 upfront 治疗 B 细胞幼淋巴细胞白血病 1 例
Invest New Drugs. 2020 Oct;38(5):1598-1600. doi: 10.1007/s10637-020-00902-9. Epub 2020 Jan 22.
5
B and T cell prolymphocytic leukaemia.B 和 T 细胞幼淋巴细胞白血病。
Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6.
6
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.泽布替尼、利妥昔单抗和来那度胺可诱导TP53突变的B细胞原淋巴细胞白血病获得深度且持久的缓解：一例病例报告及文献综述
Haematologica. 2022 May 1;107(5):1226-1228. doi: 10.3324/haematol.2021.280259.
7
Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.维奈托克可诱导伴 TP53 基因异常的高危 B 幼淋巴细胞白血病患者达到深度且持久的微小残留病灶阴性缓解。
Eur J Haematol. 2022 Nov;109(5):590-592. doi: 10.1111/ejh.13837. Epub 2022 Aug 5.
8
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.idelalisib、来那度胺和利妥昔单抗在复发难治性淋巴瘤中的安全性和耐受性：肿瘤临床试验联盟A051201和A051202 1期试验
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
9
B- and T-cell prolymphocytic leukemia: antibody approaches.B 细胞和 T 细胞前淋巴细胞白血病：抗体方法。
Hematology Am Soc Hematol Educ Program. 2012;2012:645-51. doi: 10.1182/asheducation-2012.1.645.
10
Idelalisib for treatment of B-cell malignancies.idelalisib用于治疗B细胞恶性肿瘤。
Am J Health Syst Pharm. 2016 Apr 15;73(8):547-55. doi: 10.2146/ajhp150281. Epub 2016 Mar 1.

引用本文的文献

1
Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prolymphocytic Leukemia.原发性淋巴细胞白血病患者的异基因造血干细胞移植
J Clin Med. 2025 Apr 19;14(8):2816. doi: 10.3390/jcm14082816.
2
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.慢性淋巴细胞白血病：2025年流行病学、发病机制、诊断与治疗最新进展
Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28.
3
Prolymphocytic Leukaemia: an Update on Biology and Treatment.慢性淋巴细胞白血病：生物学和治疗的最新进展。
Curr Oncol Rep. 2024 Feb;26(2):129-135. doi: 10.1007/s11912-023-01485-3. Epub 2024 Jan 2.
4
B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases.伴有P53异常的B细胞原淋巴细胞白血病经苯达莫司汀和利妥昔单抗成功治疗：三例报告
Transl Cancer Res. 2023 Jul 31;12(7):1873-1882. doi: 10.21037/tcr-23-828. Epub 2023 Jul 20.
5
B-Cell Prolymphocytic Leukemia.B细胞幼淋巴细胞白血病
J Hematol. 2023 Apr;12(2):82-86. doi: 10.14740/jh1096. Epub 2023 Apr 30.
6
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.泽布替尼、利妥昔单抗和来那度胺可诱导TP53突变的B细胞原淋巴细胞白血病获得深度且持久的缓解：一例病例报告及文献综述
Haematologica. 2022 May 1;107(5):1226-1228. doi: 10.3324/haematol.2021.280259.
7
How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.如何诊断和治疗累及脾脏的 CD5 阳性淋巴瘤。
Curr Oncol. 2021 Nov 11;28(6):4611-4633. doi: 10.3390/curroncol28060390.
8
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.伊布替尼和维奈托克治疗伴有17p缺失和TP53突变的B细胞原淋巴细胞白血病实现持续微小残留病阴性缓解
Leuk Res Rep. 2021 Aug 30;16:100266. doi: 10.1016/j.lrr.2021.100266. eCollection 2021.
9
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).一项回顾性观察研究，评估英国和爱尔兰使用idelalisib 和利妥昔单抗治疗慢性淋巴细胞白血病患者的临床结局和常规管理（RETRO-idel）。
Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14.
10
An illustrative case of B-cell prolymphocytic leukemia.B细胞幼淋巴细胞白血病的一个典型病例。
Blood Res. 2020 Sep 30;55(3):181-184. doi: 10.5045/br.2020.2020079.